Lupin announced that it has received final approval for its Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg from the United States Food and Drug Administration (FDA) to market a generic version of Concordia Pharmaceuticals Inc.’s Kapvay Extended-Release Tablets 0.1 mg.
Lupin’s Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg is the AB rated generic equivalent of Concordia Pharmaceuticals Inc.’s Kapvay Extended-Release Tablets 0.1 mg. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.
Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg had annual sales of approximately USD 66 million in the US.
Lupin Ltd is currently trading at Rs 1002.65, down by Rs 1.1 or 0.11% from its previous closing of Rs 1003.75 on the BSE.
The scrip opened at Rs 1015 and has touched a high and low of Rs 1015 and Rs 991.15 respectively. So far 9.8 lakh shares were traded on the counter. The current market cap of the company is Rs 45353.25 crore.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 1572.25 on 06-Feb-2017 and a 52 week low of Rs 920 on 21-Aug-2017. Last one week high and low of the scrip stood at Rs 1057.15 and Rs 1000.65 respectively.